Supartz (Sodium Hyaluronate) for the Treatment of Knee Osteoarthritis: A Review of Efficacy and Safety

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Review

Jacob T Neary¹  Amy Bronstone¹  Todd H Lambert¹  Vinod Dasa² 

[1] Department of Orthopaedic Surgery, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA;Vinod Dasa, Department of Orthopaedic Surgery, School of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, Box T6-7, New Orleans, LA 70112, USA. Email: ;

关键词: Knee osteoarthritis;    hyaluronic acid;    Supartz;    intra-articular injections;    viscosupplementation;   

DOI  :  10.1177/1179544119835221

 received in 2019-01-14, accepted in 2019-01-28,  发布年份 2019

来源: Sage Journals

【 摘 要 】

As concerns about the safety of systemic oral pharmacologic treatments for knee osteoarthritis (OA) mount, clinicians have increased the use of intra-articular hyaluronic acid (IA-HA) in managing mild-to-moderate knee OA. Supartz (sodium hyaluronate; Seikagaku Corporation, Tokyo, Japan) is the first IA-HA product to be approved in the world and has the longest history of global use. In this review, we summarize evidence supporting Supartz efficacy and safety, including data from pivotal clinical trials that resulted in approval of Supartz in the United States and Japan, the safety of single and repeated courses of Supartz, and Supartz efficacy using objective outcomes and in special populations. There is strong evidence that single 5-week courses of Supartz provide clinically meaningful reductions in pain and improved function for up to 6 months without risk of serious side effects or complications. Repeated courses of Supartz are as safe as single courses and have an extremely low risk of infection. Findings from promising initial studies, which suggest that Supartz may improve muscle strength, gait pattern, and balance, should be confirmed in randomized controlled trials.

【 授权许可】

CC BY-NC   
© The Author(s) 2019

【 图 表 】

Figure 7.

Figure 1